MKI67 and prostate carcinoma: Berlin et al.10 demonstrated, using meta-analysis of 21 separate studies comprising of a total of 5419 patients, that high (>6%) Ki67 levels in prostate cancer was strongly associated with poorer clinical outcome when compared with patients with lower levels of Ki67 expression.